Alisha Alaimo, Biogen US president (Biogen via YouTube)

Ex­clu­sive: Bio­gen pres­i­dent fears CMS will fi­nal­ize re­stric­tive cov­er­age de­ci­sion for Aduhelm, preps plans to flood NCD with com­ments

While lament­ing yes­ter­day’s pro­posed na­tion­al cov­er­age de­ci­sion for its con­tro­ver­sial Alzheimer’s drug, Bio­gen’s US pres­i­dent Al­isha Alaimo pledged to flood CMS with com­ments over the next 30 days in an at­tempt to en­sure the fi­nal ver­sion does not re­flect Tues­day’s draft, ac­cord­ing to an in­ter­nal email re­viewed by End­points News.

“We were pre­pared for the range of sce­nar­ios. Un­for­tu­nate­ly, this is one of the most re­stric­tive op­tions CMS could have cho­sen,” Alaimo said in an email to staff on Wednes­day. “If this draft be­comes fi­nal in April, it will sig­nif­i­cant­ly lim­it Medicare re­im­burse­ment for Aduhelm and fu­ture ther­a­pies in this class.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.